What did Russia do in August regarding the two-shot COVID-19 vaccine?

In August, Russia approved the two-shot COVID-19 vaccine for emergency use without having published extensive clinical trial data. This decision was controversial as it raised significant concerns among health experts about the safety and efficacy of the vaccine since it was based on accelerated approval processes typical of emergency situations. The lack of comprehensive data meant that the scientific community had limited information to assess the vaccine's performance and potential side effects in the broader population.

Choosing this option highlights the urgency and speed at which countries were attempting to respond to the COVID-19 pandemic, often leading to decisions that prioritized immediate public health needs over traditional regulatory processes that require substantial clinical evidence prior to approval.